Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults

1996 ◽  
Vol 135 (5) ◽  
pp. 559-567 ◽  
Author(s):  
Kamal AS AI-Shoumer ◽  
Brian Page ◽  
Elizabeth Thomas ◽  
Margaret Murphy ◽  
Salem A Beshyah ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Composition ◽  
Body Weight ◽  
Human Growth Hormone ◽  
Serum Insulin ◽  
Human Growth ◽  
Fat Free Mass ◽  
Gh Treatment ◽  
Igf I ◽  
Total Body

Al-Shoumer KAS, Page B, Thomas E, Murphy M, Beshyah SA, Johnston DG. Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults. Eur J Endocrinol 1996;135:559–67. ISSN 0804–4643 Short-term trials of growth hormone (GH) substitution in hypopituitary adults have shown beneficial effects on body composition. To evaluate the long-term effects on body composition, we followed thirteen GH-deficient adults (GH < 6 mU/l following standard provocative tests) for 4 years of GH replacement. At yearly intervals, serum insulin-like growth factor I (IGF-I), body weight, body mass index (BMI), waist, waist-to-hip circumference ratio (WHR) and resting systolic (SBP) and diastolic blood pressure (DBP) were determined, and body composition was assessed using three independent methods: total body potassium (TBK), bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA). Compared to baseline, IGF-I levels increased significantly at 1 (p = 0.0001), 2 (p = 0.0004), 3 (p = 0.006) and 4 years (p = 0.002). Body weight and BMI changed minimally at 1, 2 and 3 years and increased significantly only at the fourth year (p = 0.012 and p = 0.0009, respectively) of GH therapy. Waist and WHR decreased significantly at 1, 2 and 4 years (waist: p = 0.0009, p = 0.0004, p = 0.049; WHR: p = 0.0025, p = 0.012, p = 0.047, respectively). Neither resting SBP nor DBP changed significantly. Fat-free mass (FFM) derived from TBK and BIA increased significantly at 1 (p = 0.004; p = 0.004), 2 (p = 0.003; p = 0.05), 3 (p = 0.005; p = 0.04) and 4 years (p = 0.02; p = 0.002). Using DXA, the increase in FFM was significant at 1 (p = 0.007) and 2 years (p = 0.008) but not at 3 and 4 years. Percentage body fat measured by TBK, BIA and DXA decreased significantly at 1 (p = 0.008; p = 0.003; p = 0.03), 2 (p = 0.018; p = 0.06; p = 0.049) and 4 years (p = 0.03; p = 0.002; p = 0.04). A rise in total body water, calculated from BIA, was observed at 1 year (p = 0.004) and was maintained throughout the treatment period. These data demonstrate that 4 years of GH treatment in hypopituitary adults is associated with sustained improvement in body composition. Kamal AS Al-Shoumer, Unit of Metabolic Medicine, Imperial College School of Medicine at St. Mary's Hospital, Norfolk Place, London W2 1PG, UK

Monoclonal antibody enhancement of the effects of human growth hormone on growth and body composition in mice

1988 ◽  
Vol 117 (1) ◽  
pp. 85-90 ◽  
Author(s):  
A. T. Holder ◽  
J. A. Blows ◽  
R. Aston ◽  
P. C. Bates
Keyword(s):  
Monoclonal Antibody ◽  
Growth Hormone ◽  
Body Composition ◽  
Body Weight ◽  
Weight Gain ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Whole Body ◽  
Body Protein ◽  
Dwarf Mice

ABSTRACT Dwarf mice were treated for 10 days with phosphate-buffered saline (PBS), human growth hormone (hGH) or hGH with monoclonal antibody EB1 (hGH/MAB-EB1); for each treatment there were three groups which received 50, 75 or 100% of the amount of food eaten when available ad libitum. The PBS control groups lost more or gained less weight than equivalent groups receiving hGH alone, and mice given hGH/MAB-EB1 showed a greater weight gain than those in comparable groups receiving hGH alone. When weight gain or loss was expressed as g/g food eaten, groups treated with hGH gained more or lost less than the PBS groups. Similarly, weight gain/g food was significantly greater in hGH/MAB-EB1 animals than in the comparable groups given hGH alone. A similar pattern of response was observed for increases in tail length and uptake of 35SO42− into costal cartilage in vivo. For mice given hGH alone, fat content was decreased compared with that in the equivalent group given PBS, and mice treated with hGH/MAB-EB1 had less fat than the equivalent group given hGH alone. Administration of hGH alone caused a concomitant increase in protein content and body weight such that, compared with mice given PBS, there was no significant increase in protein as a proportion of body weight. However, hGH/MAB-EB1 caused an increase in whole body protein which was significantly greater than that for the equivalent group given hGH alone, when expressed as per cent body weight. Monoclonal antibody EB1 has been shown to enhance the actions of hGH on growth and body composition in Snell dwarf mice and to increase food conversion efficiency. J. Endocr. (1988) 117,85–90

scholarly journals Body composition in children receiving recombinant human growth hormone after renal transplantation

1998 ◽  
Vol 54 (3) ◽  
pp. 951-955 ◽  
Author(s):  
Janusz Feber ◽  
Pierre Cochat ◽  
Jan Lebl ◽  
Hana Krásničanová ◽  
Jan Štěpán ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Composition ◽  
Renal Transplantation ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth

scholarly journals Předsoutěžní redukce tělesné hmotnosti a její vliv na tělesné složení

2013 ◽  
Vol 7 (1) ◽  
pp. 121-126
Author(s):  
Klára Coufalová ◽  
Ivana Kinkorová ◽  
Lucia Malá ◽  
Jan Heller
Keyword(s):  
Body Composition ◽  
Body Weight ◽  
Weight Reduction ◽  
Negative Impact ◽  
Fat Free Mass ◽  
Extracellular Water ◽  
The Czech Republic ◽  
Body Weight Reduction ◽  
Multifrequency Bioimpedance ◽  
Total Body

The aim of our study was to monitor changes in individual components of body composition due to reduction in body weight in judo. This precontest weight reduction is very common in combat sports and it can have negative impact not only on performance but also on health. Research group consisted of 11 judoists at the age of 17-27 years belonging to the representation of the Czech Republic. The measurement of body composition had two parts; the first was before body weight reduction and the second part at the end of body weight reduction. For the measurement of body composition we used multifrequency bioimpedance analyzer BIA 2000 - M. The results of our study show that rapid intensive weight reduction is reflected in varying degrees in all parameters of body composition. We noticed a reduction of body weight by an average of 4.7% (approximately 3.8 kg), the weight loss ranged from 1.6 kg to 8.1 kg. The greatest changes in the parameters of body composition were detected in the extracellular water (ECW), there was a decrease of this parameter on average by 13.8 %, while total body water (TBW) decreased by 6.0 %. There was also a reduction in the amount of body fat by 13.2 %, the amount of extracellular mass (ECM) decreased by 9.8 %, the ratio of ECM/BCM by 8.9 % and the amount of fat-free mass (FFM) decreased by 4.0 %. Only in intracellular water (ICW), we noticed a slight increase by 1.4 %, which may be due to the redistribution of body fluids. Changes of particular parameters of body composition were statistically and substantively significant.

Human growth hormone effect on serum IGF-I and muscle function in poliomyelitis survivors

1994 ◽  
Vol 75 (8) ◽  
pp. 889-894 ◽  
Author(s):  
Krishan L. Gupta ◽  
Kaup R. Shetty ◽  
James C. Agre ◽  
Mary C. Cuisinier ◽  
Inge W. Rudman ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Muscle Function ◽  
Human Growth ◽  
Hormone Effect ◽  
Igf I

Effect of Recombinant Human Growth Hormone on Cellular Sodium Metabolism

1994 ◽  
Vol 86 (3) ◽  
pp. 233-237 ◽  
Author(s):  
Hans Herlitz ◽  
Olof Jonsson ◽  
Bengt-Åke Bengtsson
Keyword(s):  
Growth Hormone ◽  
Plasma Renin Activity ◽  
Human Growth Hormone ◽  
Total Body Water ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Plasma Renin ◽  
Body Water ◽  
Erythrocyte Sodium ◽  
Total Body

1. The effect of treatment with recombinant human growth hormone on urinary sodium excretion, total body water, the renin-angiotensin system and erythrocyte sodium metabolism was investigated in 16 adults with growth hormone deficiency. 2. Total body water was determined by isotopic dilution, and erythrocyte electrolyte contents were analysed using flame photometry. The rate of sodium influx and the efflux rate constant of sodium were calculated from values of 22Na in erythrocytes in vitro. 3. One week of treatment with recombinant human growth hormone caused a decrease in urinary sodium excretion in 9/10 patients and an increase in erythrocyte sodium content. Total body water, plasma renin activity, angiotensin II concentration and transmembrane sodium transport were unaltered. 4. Six months of treatment with recombinant human growth hormone caused significant increases in total body water, erythrocyte sodium content and sodium transmembrane influx. Plasma renin activity tended to increase, whereas blood pressure and serum sodium and potassium concentrations remained unchanged. After 6 months on recombinant human growth hormone total body water showed a significant negative correlation with plasma renin activity. 5. The enhanced erythrocyte sodium transport, if this reflects what happens in the renal tubular cell, combined with a decrease in urinary sodium excretion, during treatment with recombinant human growth hormone could indicate an increase in tubular sodium reabsorption induced by the hormone. An increased plasma renin activity associated with the lack of blood pressure rise would reinforce sodium and water retention.

Hemoglobin level is linked to growth hormone-dependent proteins in short children

Blood ◽  
1996 ◽  
Vol 87 (5) ◽  
pp. 2075-2081 ◽  
Author(s):  
E Vihervuori ◽  
M Virtanen ◽  
H Koistinen ◽  
R Koistinen ◽  
M Seppala ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Skeletal Dysplasia ◽  
Recombinant Human Growth Hormone ◽  
Body Height ◽  
Human Growth ◽  
Gh Treatment ◽  
Blood Hemoglobin ◽  
Igf I ◽  
Igfbp 3

Erythropoiesis was investigated in 32 children wih short stature and in eight children with skeletal dysplasia by studying blood hemoglobin in relation to growth and to serum concentrations of insulin-like growth factor I (IGF-I), IGF binding protein-3 (IGFBP-3), and erythropoietin (EPO) before, during, and after 12 months of recombinant human growth hormone (GH) treatment. Blood hemoglobin concentration was positively correlated with relative body height and with serum IGF-I and IGFBP-3 levels (P = .001 to .02), but not with the concentrations of EPO. The normal age-dependency of hemoglobin was lacking. Hemoglobin levels and their responses to GH treatment were similar in the patients with GH deficiency and those with normal GH secretion. Treatment with GH accelerated growth and elevated the concentrations of hemoglobin, IGF- I, and IGFBP-3. In the eight patients with skeletal dysplasia, body mass increased similarly, but gain in height was less than in the other patients, and the increase in hemoglobin was markedly pronounced. In this group, the correlations between hemoglobin, IGF-I, and IGFBP-3 were extremely close (r = 0.80 to 0.85, P = .031 to .008). These findings are in accord with earlier observations from in vitro and animal studies, and suggest that the GH-IGF axis is involved in the physiologic elevation of hemoglobin levels during childhood.

Sign in / Sign up

Export Citation Format

Share Document